Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jinming Yu
With
Roche Pharma AG
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
NSCLC confirmed by histopathology or cytology;
Stage IIA or IIIB NSCLC according to Tumor Node Metastasis (TMN) staging of Lung Staging Standard version 7 2009, and be unresectable;
Has active mutation of EGFR in exon 19 or 21;
Has measurable lesion \[according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, must have at least one evaluable lesion with the longest dimension \>= 10mm; if the evaluable lesion is lymph node, the shortest dimension should be measured and \>=15mm\];
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1;
expectancy life \>= 12 weeks;
You may not be if
Had be treated by HER-targeting agents;
Had systemic anit-NSCLC treatments;
Had local radiotherapy for NSCLC;
Has upper gastrointestinal physiological disorders, or malabsorption syndrome, or intolerance of oral medication, or active peptic ulcer;
Diagnosed other malignant tumor besides NSCLC within 5 years prior the study treatment (except having simple surgical resection with 5-year disease free survival, cured in situ of cervical carcinoma, cured basal cell carcinoma and bladder epithelial tumor);
Any evidence to indicate moderate or severe chronic obstructive pulmonary disease (COPD);
Known hypersensitivity to platinum, etoposide, EGFR-Tyrosine Kinase Inhibitor (TKI) agents or relevant components in the formulation;
Uncontrolled eye inflammation or infection, or any potential circumstances lead to eye inflammation or infection;
Clareo Health | Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21
